

PIE
218 posts










$LLY triple agonist Retatrutide demonstrated significant reductions in A1C and weight in Phase 3 trial for the treatment of type 2 diabetes. $NVO For the primary endpoint retatrutide lowered A1C by an avg of 1.7% to 2% across doses at 40 wks Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) prnewswire.com/news-releases/…






From HC wainwright on $GPCR “Our modeling and KOL feedback validate the 2.5 mg titration strategy, projecting "injectable-like" efficacy of ~17.5-19.0% in Phase 3 without the plateau seen in competitors, and with a discontinuation rate below 5%.” Not clear if projections are based on KOLs or analyst opinion but beware of the KOLs opinions in many cases in biotechs. Another example is in $SMMT lung ca OS prediction , if you exclude the top 1% lung ca real experts ( like the Emory dude ) , you see a lot of excitement among oncologists including ASCO people.





@OG_Moji69 @jakethekidt @GUnit_81 You have 0 quad 1 wins, you’re not getting in It’s that simple











